MKNK2(MNK2)
Sign in to save this workspaceUniProt Q9HBH9 · PDB · AlphaFold · Substrate: MBP · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Canertinib | 87.0% | 13.0% | 96.49 | 0.671 |
| 2 | Ponatinib | 85.3% | 14.7% | 78.23 | 0.534 |
| 3 | Cabozantinib | 77.7% | 22.3% | 92.73 | 0.751 |
| 4 | Gilteritinib | 73.7% | 26.3% | 88.97 | 0.506 |
| 5 | Osimertinib | 73.5% | 26.5% | 97.24 | 0.733 |
| 6 | Dabrafenib | 62.1% | 37.9% | 94.74 | 0.633 |
| 7 | Gefitinib | 54.3% | 45.7% | 99.25 | 0.650 |
| 8 | Afatinib | 45.9% | 54.1% | 98.50 | 0.709 |
| 9 | Sorafenib | 43.7% | 56.3% | 96.72 | 0.776 |
| 10 | Ceritinib | 42.6% | 57.4% | 95.44 | 0.618 |
| 11 | Dacomitinib | 41.8% | 58.2% | 97.99 | 0.664 |
| 12 | Brigatinib | 37.1% | 62.9% | 82.96 | 0.513 |
| 13 | Fedratinib | 34.4% | 65.6% | 96.21 | 0.576 |
| 14 | Midostaurin | 34.3% | 65.7% | 78.64 | 0.500 |
| 15 | Erlotinib | 34.0% | 66.0% | 99.75 | 0.695 |
| 16 | Vemurafenib | 33.4% | 66.6% | 96.49 | 0.598 |
| 17 | Baricitinib | 28.2% | 71.8% | 97.99 | 0.616 |
| 18 | Abemaciclib | 26.9% | 73.1% | 91.48 | 0.563 |
| 19 | Vandetanib | 26.6% | 73.4% | 95.74 | 0.723 |
| 20 | Selpercatinib | 26.3% | 73.7% | 96.72 | 0.635 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 5.08
- Epithelial log2(TPM+1): 5.65
- Fold change: -0.58
- Status: No significant change
Selectivity landscape vs inhibition on MKNK2
Each point is one of the 92 approved drugs; color = inhibition % on MKNK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…